Merger Pending
Treeline Biosciences and Standard BioTools merger
US$460m equity value
Announced 8 Jun 2026 · NASDAQ: LAB
Advisers
Acquirer
- Financial adviser
- Legal adviser
- Target
- Standard BioTools
- Target based in
- United States
- Sector
- Biotech
- Tags
- Biotech, Oncology, Drug Development
In the league tables
Similar deals
- Eli Lilly and Company acquisition of CrossBridge Bio Apr 2026 · US$300m · Biotech
- GSK acquisition of trispecific T cell-engager (TCE) asset Sep 2026 · US$750m · Biotech
- Amgen acquisition of Dark Blue Therapeutics Jan 2026 · US$840m · Biotech
- Novartis acquisition of Pikavation Mar 2026 · US$2bn · Biotech
- Eli Lilly and Company acquisition of Ajax Therapeutics Apr 2026 · US$2.3bn · Biotech
Sources
- 8 Jun 2026 Press release (EX-99.1, exhibit), Standard BioTools and Treeline Biosciences Announce sec.gov
- 8 Jun 2026 Freshfields Advises Standard BioTools on its Merger Agreement With Treeline Biosciences freshfields.com
